J&J division loses Risperdal lawsuit in Ark.

04/10/2012 | Bloomberg Businessweek

An Arkansas jury determined that Janssen Pharmaceuticals, a Johnson & Johnson unit, misled patients and physicians about the risks of antipsychotic Risperdal. The state attorney general's office seeks at least $1.2 billion in penalty. "Janssen firmly believes it did not violate the Arkansas Medicaid Fraud False Claims Act or the Arkansas consumer fraud statute," the company said.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ